Engineers Gate Manager LP Kodiak Sciences Inc. Transaction History

Engineers Gate Manager LP

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	BUY	$1.4 - $3.24 $31,203 - $72,213	22,288 New	22,288 $67,000
Q1 2023 May 15, 2023	BUY	$4.81 - $8.88 $17,623 - $32,536	3,664 Added 34.63%	14,245 $88,000
Q4 2022 Feb 14, 2023	SELL	$6.52 - $8.05 $8,163 - $10,078	-1,252 Reduced 10.58%	10,581 $75,000
Q3 2022 Nov 14, 2022	SELL	$7.57 - $12.5 $136,767 - $225,837	-18,067 Reduced 60.42%	11,833 $92,000
Q2 2022 Aug 15, 2022	BUY	$5.04 - $9.48 $28,728 - $54,036	5,700 Added 23.55%	29,900 $228,000
Q1 2022 May 16, 2022	BUY	$7.09 - $89.45 $171,578 - $2.16 Million	24,200 New	24,200 $187,000
Q3 2020 Nov 16, 2020	SELL	$45.05 - $59.27 $487,981 - $642,012	-10,832 Closed	0 $0
Q2 2020 Aug 17, 2020	BUY	$42.74 - $66.25 $462,959 - $717,620	10,832 New	10,832 $586,000

39M

6.5K

5.8K

Ticker KOD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 52,040,200
Market Cap $455M
Description
Kodiak Sciences Inc., a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is KSI-301, an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as we...

Get notified when there are updates to the investment portfolio of Engineers Gate Manager LP, based on Form 13F filings with the SEC.

Stay updated on Engineers Gate Manager LP with notifications on news.